<DOC>
	<DOCNO>NCT01187368</DOCNO>
	<brief_summary>The objective pivotal study assess safety efficacy EVAHEART LVAS bridge-to-transplant subject end stage heart failure . Subjects follow 180 day EVAHEART LVAS implant cardiac transplant explant recovery ( + 60 day discharge ) . If 180 day post-implant subject receive cardiac transplant device explanted , subject continue follow monthly .</brief_summary>
	<brief_title>EVAHEART LVAS Bridge-to-Transplant Pivotal Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>The following list general inclusion criterion : Age ≥ 18 year Listed cardiac transplant status 1A 1B NYHA Class IV heart failure Patient able provide write informed consent More detailed inclusion criterion information note study protocol The following list general exclusion criterion : Active , uncontrolled infection BSA &lt; 1.4 m² Irreversible organ failure Severe right ventricular failure Prosthetic mechanical aortic mitral valve Patients unacceptable risk successful LVAD implantation maintenance Patients refuse blood transfusion Intolerant anticoagulation therapy Coagulopathy Active psychiatric disorder , irreversible cognitive dysfunction psychosocial behavior impairs ability patient follow instruction , maintain device medical regimen Pregnancy Current dependence mechanical circulatory support device time implant , IABP Presence condition heart failure would limit survival less 3 year More detailed exclusion criterion information note study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>heart failure</keyword>
	<keyword>LVAS</keyword>
	<keyword>LVAD</keyword>
	<keyword>bridge-to-transplant</keyword>
	<keyword>rotary pump</keyword>
</DOC>